China's Robot Champion Goes Public — With a Pentagon Shadow
Unitree closed its first trading session up more than 460%, lifting the Hangzhou-based humanoid-robot maker to a market capitalization of roughly $66 billion. The company had priced its IPO on Shanghai's STAR Market at a $9 billion valuation, raising around $900 million in the process. One session later, it sits ahead of Baidu and JD.com in market value — and well clear of Figure AI, the most valuable U.S. robotics company, which was valued at $39 billion in a September 2025 funding round.
The numbers behind the business are real, if still modest relative to the hype. Unitree reported 1.7 billion yuan ($252 million) in revenue for 2025 and 600 million yuan ($89 million) in profit. Nearly 45% of sales came from overseas, with the United States alone accounting for 18% of total revenue. Backers include Alibaba, Ant Group, Tencent, DeepSeek, and several state-backed investment funds — a coalition that signals Beijing's strategic interest in the sector as much as private capital conviction.
Nomura initiated coverage with a 'buy' rating, crediting Unitree's 'rapid product iteration and continuous innovation' as the foundation of a 'first-mover advantage.' Days before the listing, the company unveiled its 'Superman' robot, which it claimed can beat human records on jumping height and running speed. Synchronized performances by Unitree humanoids are now a fixture of China's CCTV Spring Festival Gala, and founder Wang Xingxing was among the tech leaders invited to meet President Xi Jinping in 2025.
Yet the rally carries a visible fault line. In late July, the U.S. imposed a ban on foreign-made robots, citing national security concerns — models already sold in the U.S. are exempt, but new shipments are blocked. The Pentagon has separately placed Unitree on its list of 'Chinese military companies.' Morningstar analyst Kangyuxiao Li, writing the day before the debut, warned that 'losing access could noticeably affect revenue growth — particularly because the company has been among the most successful Chinese firms at selling relatively low-cost robots overseas.' Beyond lost sales, Li noted that Unitree could also forfeit valuable product feedback from U.S. customers.
Skepticism runs deeper than geopolitics. HSBC analysts wrote in a mid-July report that 'the surge in shipments for robot makers could be illusionary,' arguing that without significant improvement in AI model capability, 'the current humanoid robot shipment upcycle is unlikely to be sustained over the next 1-2 years.' Most of Unitree's current sales still go toward research purposes, not commercial deployment at scale.
A large first-day pop is structurally common for Chinese IPOs: mainland regulators deliberately keep listing prices low to protect retail investors, engineering the appearance of a blowout debut. ChangXin Memory Technologies surged by the same 460% figure on its own Shanghai debut on July 27.
CEO Times take: The Unitree listing is a clean illustration of how Beijing deploys capital markets as industrial policy — suppressed IPO prices, state-fund backing, and national-champion branding all working in concert. For American free enterprise, the lesson is uncomfortable: a competitor nurtured by the Chinese state now outvalues every U.S. robotics firm by a wide margin. Washington's foreign-robot ban addresses a real security concern, but it also removes the market discipline that U.S. customer feedback would have imposed on Unitree's product development. Capital rewards clear rules; right now, the rules on both sides of the Pacific are being written by governments, not markets.
